In short
E2814 is an investigational drug currently being studied in clinical trials for its potential to treat Alzheimer's disease. This article provides an overview of the ongoing research into E2814, including its safety, efficacy, and potential benefits for patients with early-stage Alzheimer's and those at risk for inherited forms of the disease.
At a glance
- Drug Name
- E2814
- Target
- Tau protein in Alzheimer's disease
- Administration
- Intravenous infusion, typically every 4 weeks
- Patient Population
- Early Alzheimer's disease, including mild to moderate cognitive impairment; some studies focus on dominantly inherited Alzheimer's disease (DIAD)
- Study Objectives
- Safety, tolerability, pharmacokinetics, pharmacodynamics, biomarker effects, cognitive outcomes
- Combination Therapy
- Some trials studying E2814 in combination with lecanemab (anti-amyloid drug)
- Key Measurements
- Cerebrospinal fluid (CSF) tau levels, tau PET imaging, cognitive assessments, safety parameters
- Trial Phases
- Phase 1, 2, and 2/3 studies ongoing
What is E2814?
E2814 is an investigational drug being studied as a potential treatment for Alzheimer's disease. It is a type of medication called an antibody, which is designed to target specific proteins in the body. In this case, E2814 targets a protein called tau, which is believed to play a role in the development of Alzheimer's disease.
How E2814 Works
E2814 works by binding to a specific part of the tau protein called the microtubule-binding region (MTBR). This region is important because it's involved in the formation of tau aggregates, which are clumps of tau protein that can damage brain cells. By binding to this region, E2814 aims to disrupt the formation of these harmful aggregates and potentially slow down the progression of Alzheimer's disease.
Conditions Treated by E2814
E2814 is primarily being studied for the treatment of Alzheimer's disease, including: Early Alzheimer's disease: This refers to the early stages of the condition when symptoms are mild. Dominantly Inherited Alzheimer's Disease (DIAD): This is a rare form of Alzheimer's caused by specific genetic mutations.
Clinical Trials Involving E2814
Several clinical trials are currently underway to evaluate the safety and effectiveness of E2814: Phase 1 studies: These early studies are assessing the safety, tolerability, and how the drug moves through the body (pharmacokinetics) in healthy volunteers. Phase 1b/2 studies: These trials are evaluating E2814 in people with mild to moderate cognitive impairment due to Alzheimer's disease. Phase 2/3 studies: Larger trials are investigating the potential benefits of E2814 in combination with other Alzheimer's treatments.
How E2814 is Administered
E2814 is given as an intravenous (IV) infusion, which means it's delivered directly into the bloodstream through a vein. In clinical trials, it's typically administered every four weeks (Q4W). The exact dosage and frequency may vary depending on the specific trial and treatment plan.
E2814 in Combination Therapy
Some clinical trials are studying E2814 in combination with another drug called lecanemab (also known as BAN2401). Lecanemab is an antibody that targets a different protein involved in Alzheimer's disease called amyloid. The goal of combining these treatments is to potentially enhance their effectiveness by targeting multiple aspects of the disease process.
Safety and Side Effects
As E2814 is still in clinical trials, its full safety profile and potential side effects are not yet fully known. The ongoing studies are carefully monitoring participants for: Treatment-emergent adverse events (TEAEs): These are any new medical problems or worsening of existing problems that occur during treatment. Serious adverse events (SAEs): These are more severe or life-threatening side effects. Changes in laboratory values, vital signs, and electrocardiogram (ECG) findings. Development of antibodies against E2814, which could potentially affect its effectiveness. It's important to note that as an investigational drug, E2814 is not yet approved for general use and is only available through clinical trials. Patients interested in learning more about E2814 should consult with their healthcare providers and consider participating in clinical trials if eligible.